Skip to main content

VTYX

Stock
Health Care
Biotechnology

Performance overview

VTYX Price
Price Chart

Forward-looking statistics

Beta
1.02
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

we are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. ventyx now includes combined assets from three separate companies: oppilan pharma, targeting s1p1r, zomagen biosciences, targeting nlrp3 and the inflammasome, and ventyx biosciences, targeting tyk2.

Company info

SectorHealth Care
IndustryBiotechnology
Employees44
Market cap$229.8M

Fundamentals

Enterprise value-$66.0M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity4.55

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.74
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$7M
Avg trading volume (10 day)$6M
Put-call ratio—

Macro factor sensitivity

Growth-2.4
Credit+8.8
Liquidity+0.9
Inflation-4.8
Commodities+0.2
Interest Rates+0.4

Valuation

Dividend yield0.00%
PEG Ratio-0.96
Price to sales—
P/E Ratio-0.96
Enterprise Value to Revenue—
Price to book0.63

Upcoming events

Next earnings dayMay 10, 2024
Next dividend day—
Ex. dividend day—

News

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Ventyx Biosciences (VTYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research (July 10, 2025)
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX.

Benzinga (September 23, 2024)
You can start to dip your toes into biotech here, says Jefferies' Yee

Jefferies' Michael Yee joins 'Closing Bell' to discuss biotech stocks, which were one of the worst performers in today's sell-off. With CNBC's Michael Santoli.

CNBC Television (September 2, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free